News - ARID1A deletion

10ms

Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion (PubMed, Zhonghua Bing Li Xue Za Zhi)

Postoperative adjuvant chemotherapy was given to three patients. AFP-producing adenocarcinoma is a rare subtype of gastric cancer, which can be combined with SWI/SNF complex deletion, and the pathomorphological manifestations are different from the classical SWI/SNF complex deletion of undifferentiated carcinoma with rhabdoid phenotype.

10 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDH1 (Cadherin 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • AFP (Alpha-fetoprotein) • GPC3 (Glypican 3) • SALL4 (Spalt Like Transcription Factor 4) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)

ARID1A deletion • SMARCA4 deletion • SMARCB1 deletion • CDH1 expression • GPC3 expression • AFP expression

1year

SWI/SNF Chromatin Remodeling Complex Orchestrates Sequential Binding of Key Transcription Factors in B Cells and Restricts Aggressive Lymphoma (ASH 2023)

Remarkably, we further show that FL patients with ARID1A-inactivating mutations display an immature memory B-cell-like state with increased transformation risk to aggressive disease (p=0.0391). These observations offer mechanistic understanding into the emergence of both indolent and aggressive lymphomas in ARID1A-mutant patients through formation of immature memory-like clonal precursors.

1 year ago

IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • IL6 (Interleukin 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD40 (CD40 Molecule) • IL4 (Interleukin 4) • CD80 (CD80 Molecule)

ARID1A mutation • ARID1A deletion

over1year

ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer. (PubMed, Curr Med Sci)

Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.

over 1 year ago

Journal

ARID1A (AT-rich interaction domain 1A) • EIF4A3 (Eukaryotic Translation Initiation Factor 4A3)

ARID1A mutation • ARID1A deletion

cisplatin

over2years

ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications. (PubMed, Diagn Pathol)

We report an ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate, adding to the growing spectrum of SWI/SNF driven undifferentiated sarcoma. Rhabdoid cells can be a helpful morphological clue for promoting molecular and immunohistochemical analyses for deficiency of SWI/SNF subunits, in the diagnostic workup of undifferentiated neoplasms featuring epithelioid or rhabdoid morphology.

over 2 years ago

Journal

ARID1A (AT-rich interaction domain 1A) • CD34 (CD34 molecule) • VIM (Vimentin)

ARID1A mutation • ARID1A deletion

cisplatin • doxorubicin hydrochloride • ifosfamide • etoposide IV

over3years

A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. (PubMed, Lab Invest)

Drug screening demonstrates that both HDAC inhibitor and PARP inhibitor are effective in targeting cells with ARID1A deletion. Together, our data support the potential of hEM3 as a cell line model for studying the pathobiology of endometrium-related diseases and for developing effective precision therapies.

over 3 years ago

Preclinical • Journal • PARP Biomarker

ARID1A (AT-rich interaction domain 1A) • PAX8 (Paired box 8)

ARID1A deletion

over3years

Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. (PubMed, Cancer Discov)

ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could impact treatment strategies in MBC.

over 3 years ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CDH1 (Cadherin 1) • MDM4 (The mouse double minute 4) • GATA1 (GATA Binding Protein 1)

TP53 mutation • TMB-H • HER-2 negative • PIK3CA mutation • PTEN mutation • ARID1A mutation • MYC amplification • RB1 mutation • ARID1A deletion • MDM4 amplification • MDM4 mutation

4years

Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. (PubMed, Nat Commun)

Using a system biology approach and functional studies, we demonstrate that ARID1A-deficiency lead to loss of TGF-β tumor suppressive function and that inactivation of ARID1A/TGF-β axis promotes migration and invasion of PTEN-deleted endometrial tumor cells. These findings provide molecular insights into how ARID1A inactivation accelerates endometrial tumor progression and dissemination, the major causes of cancer mortality.

4 years ago

Journal

PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A)

PTEN deletion • PTEN mutation • ARID1A mutation • ARID1A deletion